基于Tegoprazan与基于esomeprazole的三重疗法加上对Helicobacter pylori的第一线根除:全国性的,多中心的,双盲的,随机对照的试验
Zhiqiang Song1, Weihong Wang2, Peng Li3
1Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China.
Chinese medical journal
|August 22, 2025
概括
与以索梅普拉为基础的TTPB相比,基于Tegoprazan的三重疗法加上 (TTPB) 在消灭Helicobacter pylori方面显示出非劣势性和更高的疗效,安全性和遵守性相似.
科学领域:
- 胃肠病学
- 传染性疾病
- 药理学
背景情况:
- 三重治疗加上 (TTPB) 是一种标准的Helicobacter pylori (H. pylori) 根除治疗方法.
- 根除率低于最佳需要改进治疗策略.
- 与质子抑制剂 (PPI) 相比,与竞争性酸阻断剂 (P-CABs) 提供更强的胃酸抑制作用.
研究的目的:
- 为了比较基于泰戈普拉桑的TTPB (TACB) 与基于埃索梅普拉的TTPB (EACB) 的疗效,安全性和合规性.
- 评估TACB作为之前未接受治疗的患者的H. pylori根除的潜在替代方案.
主要方法:
- 一个全国性的多中心,双盲,随机对照试验,涉及561名H. pylori感染患者.
- 患者接受了TACB (特戈普拉桑,阿莫西林,明素,斯木斯) 或EACB (埃索莫普拉,阿莫西林,明素,斯木斯) 14天.
- 通过13C尿素呼吸试验证实了H. pylori的根除;主要终点是全分析组 (FAS) 的根除率.
主要成果:
- 在FAS群体中,以泰戈普拉桑为基础的TTPB的根除率明显高 (93. 5%),而以埃索梅普拉为基础的TTPB (86. 4%) 则高 (P = 0. 006).
- 基於Tegoprazan的TTPB與基於esomeprazole的TTPB沒有劣勢,兩組之間的差異為7. 0%.
- 治疗引起的不良事件和遵守率在两组之间是可比的.
结论:
- 与以索梅普拉为基础的TTPB相比,Tegoprazan是H. pylori根除的非劣质且潜在的优质选择.
- TACB和EACB的安全性和合规性是相似的.
- 这项研究支持在H. pylori根除方案中使用P-CABs.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
546
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
546
Peptic Ulcer Disease IV: Management
145
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
145
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
200
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
200
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
525
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
525
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
569
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
569
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
687
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
687


